As Teva Pharmaceutical Inds LTD (TEVA) Market Value Declined, Holder Employees Retirement System Of Texas Has Decreased Its Holding by $6.21 Million

July 17, 2017 - By Adrian Mccoy

Employees Retirement System Of Texas decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 16.44% based on its latest 2016Q4 regulatory filing with the SEC. Employees Retirement System Of Texas sold 172,570 shares as the company’s stock declined 15.11% while stock markets rallied. The institutional investor held 876,865 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $31.79M, down from 1.05 million at the end of the previous reported quarter. Employees Retirement System Of Texas who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $32.40B market cap company. The stock declined 0.05% or $0.01 reaching $31.89 per share. About 5.66M shares traded. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since July 17, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Employees Retirement System Of Texas, which manages about $7.34B US Long portfolio, upped its stake in Acuity Brands Inc (NYSE:AYI) by 18,000 shares to 21,800 shares, valued at $5.03 million in 2016Q4, according to the filing. It also increased its holding in Dr Pepper Snapple Group Inc (NYSE:DPS) by 64,000 shares in the quarter, for a total of 76,000 shares, and has risen its stake in Us Bancorp Del (NYSE:USB).

More notable recent Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) news were published by: Investorplace.com which released: “Why Cyberark Software Ltd (CYBR), Teva Pharmaceutical Industries Ltd (ADR …” on July 14, 2017, also Investorplace.com with their article: “Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back” published on July 17, 2017, Investorplace.com published: “Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock: Time to Go Contrarian?” on June 19, 2017. More interesting news about Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) were released by: Benzinga.com and their article: “Analyst Wonders If AstraZeneca’s CEO Would Be A Fit At Teva” published on July 13, 2017 as well as Benzinga.com‘s news article titled: “Najarian Brothers See Unusual Options Activity In Energy Transfer Equity And …” with publication date: July 06, 2017.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage

Among 26 analysts covering Teva Pharma (NYSE:TEVA), 12 have Buy rating, 0 Sell and 14 Hold. Therefore 46% are positive. Teva Pharma had 68 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Argus Research given on Tuesday, July 28. Oppenheimer maintained the shares of TEVA in report on Friday, July 14 with “Buy” rating. Oppenheimer maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Friday, April 7 with “Buy” rating. As per Friday, October 30, the company rating was reinitiated by Jefferies. As per Friday, January 6, the company rating was downgraded by Maxim Group. Oppenheimer reinitiated Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday, December 7 with “Outperform” rating. On Tuesday, July 28 the stock rating was maintained by Deutsche Bank with “Buy”. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Mizuho on Thursday, August 25. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Maxim Group on Monday, July 27. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Neutral” rating given on Friday, January 20 by JP Morgan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.